Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Arcutis Biotherapeutics, Inc. Fourth Quarter Fiscal Year 2025 Earnings Conference Call.
Arcutis Biotherapeutics Inc. (ARQT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Suvretta Capital Management Aaron Cowen | 11,964,000 | $347,434,560 | +15% | 7.12% |
| 2. | Rubric Capital Management David Rosen | 8,271,577 | $240,206,596 | -24% | 2.87% |
| 3. | Polar Capital Brian Ashford-Russell And Tim Woolley | 5,556,169 | $161,351,148 | +5% | 0.62% |
| 4. | D E Shaw D. E. Shaw | 2,683,087 | $77,916,846 | +27% | 0.04% |
| 5. | Driehaus Capital Richard Driehaus | 2,562,445 | $74,413,403 | +134% | 0.51% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.08 | 2,646 | $34,610.47 | 27,448 | 2025-06-13 | Filing | |
| $13.41 | 378 | $5,069.28 | 24,802 | 2025-06-05 | Filing | |
| $13.32 | 1,890 | $25,177.45 | 24,424 | 2025-06-04 | Filing | |
| $13.65 | 2,520 | $34,398.00 | 22,534 | 2025-05-22 | Filing | |
| $13.66 | 2,520 | $34,423.20 | 20,014 | 2025-05-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.63 | 4,714 | $120,819.82 | 110,003 | 2026-02-02 | Filing | |
| $25.24 | 19,379 | $489,125.96 | 114,717 | 2026-02-02 | Filing | |
| $24.97 | 8,562 | $213,793.14 | 134,096 | 2026-02-02 | Filing | |
| $25.50 | 7,983 | $203,553.73 | 142,658 | 2026-02-02 | Filing | |
| $25.81 | 9,794 | $252,747.88 | 80,651 | 2026-02-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,874,511 | $286,755,799 | 7.7% | |
| 2. | 9,099,579 | $264,251,774 | 0% | |
| 3. | 7,253,936 | $210,654,301 | 0% | |
| 4. | 6,758,006 | $196,252,495 | 0.12% | |
| 5. | 5,488,301 | $159,380,261 | 0.01% |
News See All
Baron Health Care Fund is Expecting High Operating Margins for Arcutis Biotherapeutics (ARQT)
Baron Funds, an investment management company, released its fourth-quarter investor letter for the “Baron Health Care Fund”. A copy of the letter can be downloaded here.
Arcutis (ARQT) Soars to Record High on Swing to Profitability, 'More-Than-Double' Revenues
Arcutis jumped to a fresh record high on Tuesday, as investors cheered a stellar earnings performance in the third quarter of the year, having more than doubled its revenues to reach profitability during...
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2025 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2025 Earnings Call Transcript October 28, 2025Arcutis Biotherapeutics, Inc. beats earnings expectations.
Arcutis Biotherapeutics, Inc. (ARQT) Eyes Pediatric Expansion for ZORYVE Cream
Arcutis Biotherapeutics, Inc.
11 Best Performing Biotech Stocks So Far in 2025
On July 8, Jared Holz of Mizuho spoke on CNBC's "Closing Bell Overtime" about whether the biotech sector is ready for a breakthrough.
Arcutis Biotherapeutics Submits Supplemental New Drug Application to FDA For ZORYVE
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 14 Best Small Cap Stocks to Buy Right Now. On September 3, Arcutis Biotherapeutics, Inc.
14 Best Small Cap Stocks to Buy Right Now
The S&P 600 and S&P BSE Small Cap indexes had soared 0.29% and 0.30%, respectively, while the Russell 2000 has jumped nearly 0.48% as of September 8. The U.S.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q2 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Arcutis Biotherapeutics 2025 Second Quarter Financial Results Conference Call.
Arcutis' ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis
Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, Arcutis Biotherapeutics Inc.